echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Plant Extracts News > Hawthorn extract can extend the life of patients with heart failure

    Hawthorn extract can extend the life of patients with heart failure

    • Last Update: 2013-06-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The drug extracted from hawthorn is WS · 1442, which can safely prolong the life of patients with congestive heart failure who have received drug treatment WS · 1442 is a natural antioxidant extracted from hawthorn leaves In some European countries, it has been approved for the treatment of early congestive heart failure Acc.07 is the most authoritative conference of cardiovascular medicine Cardiologists and cardiovascular experts often gather here to promote further breakthroughs in the field of cardiovascular medicine 156 research centers in Europe jointly carried out the famous randomized double-blind clinical trial spice study Eighty four percent of the subjects in the study were men According to the New York Heart Association heart function grading standard, 44% of the patients' heart function is grade III, which means their heart function is seriously damaged The end point of the study was the first cardiac event: sudden cardiac death, death due to progressive heart failure, fatal heart attack, nonfatal heart attack or heart failure requiring hospitalization A total of 2681 patients with significant left ventricular dysfunction were randomly assigned to the WS · 442 or placebo group for two years of continuous treatment All patients have received ACEI (83%), beta blocker (64%), cardiotonic glycoside (57%), spironolactone (39%) or diuretic (85%) Professor holubarsch and his team found that in the first 18 months of the study, patients in the WS · 1442 group had a 20% reduction in cardiac mortality and a four month increase in life expectancy Compared with placebo group, WS · 1442 group had a lower incidence of adverse events, which proved the safety of the compound Professor holubarsch reported that "in patients with more severe congestive heart failure and patients with left ventricular ejection fraction less than 35%, the use of WS · 1442 is also safe In an important study subgroup, WS 14422 delayed the incidence of cardiac death and sudden cardiac death "
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.